EYPT

Company Overview — What Does EyePoint Pharmaceuticals, Inc. Do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals, Inc. (EYPT) is classified as a small-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO Nancy S. Lurker and employs approximately 120 people, headquartered in WATERTOWN, Massachusetts. With a market capitalization of $1.1B, EYPT is one of the notable companies in the Technology sector.

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Rating — Reduce (April 2026)

As of April 2026, EyePoint Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 36.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.EYPT ranks #3,338 out of 4,446 stocks in our coverage universe. Within the Technology sector, EyePoint Pharmaceuticals, Inc. ranks #393 of 584 stocks, placing it in the lower half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EYPT Stock Price and 52-Week Range

EyePoint Pharmaceuticals, Inc. (EYPT) currently trades at $14.19. The stock lost $0.04 (0.3%) in the most recent trading session. The 52-week high for EYPT is $19.11, which means the stock is currently trading -25.7% from its annual peak. The 52-week low is $3.91, putting the stock 262.9% above its annual trough. Recent trading volume was 742K shares, suggesting relatively thin trading activity.

Is EYPT Overvalued or Undervalued? — Valuation Analysis

EyePoint Pharmaceuticals, Inc. (EYPT) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.70x, versus the sector average of 3.16x. The price-to-sales ratio is 27.43x, compared to 1.06x for the average Technology stock.

At current multiples, EyePoint Pharmaceuticals, Inc. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

EyePoint Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

EyePoint Pharmaceuticals, Inc. (EYPT) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -63.3%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.2% versus the sector average of -1.0%.

On a margin basis, EyePoint Pharmaceuticals, Inc. reports gross margins of 93.0%, compared to 50.9% for the sector. The operating margin is -2024.6% (sector: -0.5%). Net profit margin stands at -1940.4%, versus -1.5% for the average Technology stock. Revenue growth is running at -89.8% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EYPT Debt, Balance Sheet, and Financial Health

EyePoint Pharmaceuticals, Inc. has a debt-to-equity ratio of 19.0%, compared to the Technology sector average of 43.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $75M.

EYPT has a beta of 1.07, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for EyePoint Pharmaceuticals, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

EyePoint Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, EyePoint Pharmaceuticals, Inc. reported revenue of $41M and earnings per share (EPS) of $-3.17. Net income for the quarter was $-194M. Gross margin was 93.0%. Operating income came in at $-206M.

In FY 2025, EyePoint Pharmaceuticals, Inc. reported revenue of $31M and earnings per share (EPS) of $-3.17. Net income for the quarter was $-232M. Revenue grew -27.5% year-over-year compared to FY 2024. Operating income came in at $-243M.

In Q3 2025, EyePoint Pharmaceuticals, Inc. reported revenue of $966,000 and earnings per share (EPS) of $-0.85. Net income for the quarter was $-60M. Revenue grew -90.8% year-over-year compared to Q3 2024. Operating income came in at $-62M.

In Q2 2025, EyePoint Pharmaceuticals, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.85. Net income for the quarter was $-59M. Revenue grew -43.7% year-over-year compared to Q2 2024. Operating income came in at $-62M.

Over the past 8 quarters, EyePoint Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $9M to $41M. Investors analyzing EYPT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EYPT Dividend Yield and Income Analysis

EyePoint Pharmaceuticals, Inc. (EYPT) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

EYPT Momentum and Technical Analysis Profile

EyePoint Pharmaceuticals, Inc. (EYPT) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

EYPT vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, EyePoint Pharmaceuticals, Inc. (EYPT) ranks #393 out of 584 stocks based on the Blank Capital composite score. This places EYPT in the lower half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing EYPT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EYPT vs S&P 500 (SPY) comparison to assess how EyePoint Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

EYPT Next Earnings Date

No upcoming earnings date has been announced for EyePoint Pharmaceuticals, Inc. (EYPT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EYPT? — Investment Thesis Summary

The quantitative profile for EyePoint Pharmaceuticals, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 36/100) increases portfolio risk.

In summary, EyePoint Pharmaceuticals, Inc. (EYPT) earns a Reduce rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EYPT stock.

Related Resources for EYPT Investors

Explore more research and tools: EYPT vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EYPT head-to-head with peers: EYPT vs IHS, EYPT vs VRSN, EYPT vs ESE.